Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan-Dec:35:1533317519899546.
doi: 10.1177/1533317519899546.

Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS

Hayato Akimoto  1 , Akio Negishi  1 , Shinji Oshima  1 , Haruna Wakiyama  1 , Mitsuyoshi Okita  2 , Norimitsu Horii  2   3 , Naoko Inoue  2   3 , Shigeru Ohshima  2   3 , Daisuke Kobayashi  1
Affiliations

Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS

Hayato Akimoto et al. Am J Alzheimers Dis Other Demen. 2020 Jan-Dec.

Abstract

Alzheimer disease (AD) may develop after the onset of type 2 diabetes mellitus (T2DM), and the risk of AD may depend on the antidiabetic drug administered. We compared the risk of AD among 66 085 patients (≥ 65 years) with T2DM (1250 having concomitant AD) who had been administered antidiabetic drug monotherapy for T2DM who had voluntarily reported themselves in the Food and Drug Administration Adverse Event Reporting System. The risk of AD from the use of different antidiabetic drug monotherapies compared to that of metformin monotherapy was assessed by logistic regression. Rosiglitazone (adjusted reporting odds ratio [aROR] = 0.11; 95% confidence interval [CI]: 0.07-0.17; P < .001), exenatide (aROR = 0.22; 95% CI: 0.11-0.37; P < .001), liraglutide (aROR = 0.36; 95% CI: 0.19-0.62; P < .001), dulaglutide (aROR = 0.39; 95% CI: 0.17-0.77; P = .014), and sitagliptin (aROR = 0.75; 95% CI: 0.60-0.93; P = .011) were found to have a significantly lower associated risk of AD than that of metformin. Therefore, the administration of glucagon-like peptide 1 receptor agonists and rosiglitazone may reduce the risk of AD in patients with T2DM.

Keywords: Alzheimer disease; FDA adverse event reporting system; antidiabetics; dementia; type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Flowchart of patient data selection for risk assessment. AD indicates Alzheimer disease; FAERS, Food and Drug Administration Adverse Event Reporting System.
Figure 2.
Figure 2.
Risk of development of Alzheimer disease using the different antidiabetic drug therapies compared to metformin. Lixisenatide was excluded from the analysis since no relevant cases were extracted (Table 2). Antidiabetic drugs for which there were 0 patients with concomitant Alzheimer disease (chlorpropamide, tolazamide, albiglutide, canagliflozin, and dapagliflozin) were not included in this figure since the adjusted reporting odds ratio (aROR) could not be accurately calculated, and there was a large variance.
Figure 3.
Figure 3.
Risk associated with the development of Alzheimer disease with the use of different antidiabetic drug therapies in male patients. Lixisenatide was excluded from the analysis, since no relevant cases were extracted (Table 2). Antidiabetic drugs for which there were 0 patients with concomitant Alzheimer disease (acarbose, chlorpropamide, tolazamide, albiglutide, canagliflozin, and dapagliflozin) are not included in this figure since the adjusted reporting odds ratio (aROR) could not be accurately calculated and large variance was present.
Figure 4.
Figure 4.
Risk associated with the development of Alzheimer disease with the use of different antidiabetic drug therapies in female patients. Lixisenatide was excluded from the analysis since no relevant cases were extracted (Table 2). Antidiabetic drugs for which there were 0 patients with concomitant Alzheimer disease (chlorpropamide, tolazamide, tolbutamide, albiglutide, canagliflozin, and dapagliflozin) are not included in this figure, as the adjusted reporting odds ratio (aROR) could not be accurately calculated and large variance was present.
See this image and copyright information in PMC

References

    1. Brookmeyer R, Abdalla N, Kawas CH, Corrada MM. Forecasting the prevalence of preclinical and clinical Alzheimer’s disease in the United States. Alzheimers Dement. 2018;14(2):121–129. - PMC - PubMed
    1. Alzheimer’s Association. 2016 Alzheimer’s disease facts and figures. Alzheimers Dement. 2016;12(4):459–509. - PubMed
    1. Evin G, Weidemann A. Biogenesis and metabolism of Alzheimer’s disease Abeta amyloid peptides. Peptides. 2002;23(7):1285–1297. - PubMed
    1. Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184–185. - PubMed
    1. Barage SH, Sonawane KD. Amyloid cascade hypothesis: pathogenesis and therapeutic strategies in Alzheimer’s disease. Neuropeptides. 2015;52:1–18. - PubMed

MeSH terms